Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral

13.12.2022 - Takeda (TSE:4502/NYSE:TAK) today announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases ...

Related Keywords

Japan , Boston , Massachusetts , United States , Osaka , Cambridge , Cambridgeshire , United Kingdom , Catherine Wilson , Nimbus Therapeutics , Takeda Yakuhin Kogyo , Jeb Keiper , Jun Saito , Christopher Oreilly , Research Development At Takeda , Nimbus Lakshmi Inc , Exchange Commission , Cleary Gottlieb Steen Hamilton , Takeda Pharmaceutical Company Limited , Program Subsidiary , Evercore Group , Andy Plump , Costa Saroukos , Antitrust Improvements Act , Cleary Gottlieb Steen , Rare Genetics , Plasma Derived Therapies , Pharmaceutical Company Limited , Annual Report , Nimbus Lakshmi , Acquire Late Stage , Potential Best In Class , Oral Allosteric , Wharf Road , Chief Executive Officer , Common Stock , Seriesb Common Stock , Rare Genetic , Takeda Yakuhin Kogyo Stock ,